TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Maschietto, Mariana ^a   Williams, Richard D ^a   Chagtai, Tasnim ^a   Popov, Sergey D ^b   Sebire, Neil J ^c   Vujanic, Gordan ^d   Perlman, Elizabeth ^e   Anderson, James R ^f   Grundy, Paul ^g   Dome, Jeffrey S ^h   Pritchard Jones, Kathy ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN P53; TP53 PROTEIN, HUMAN; TRANSCRIPTOME; TUMOR MARKER;

ANAPLASTIC CARCINOMA; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CELL CYCLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DEREGULATION; DNA REPAIR; EVENT FREE SURVIVAL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENOMIC INSTABILITY; HUMAN; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; NEPHROBLASTOMA; OVERALL SURVIVAL; RECURRENCE RISK; WILD TYPE; CHILD; DNA MUTATIONAL ANALYSIS; FRAMESHIFT MUTATION; GENETIC ASSOCIATION STUDY; GENETICS; INFANT; KIDNEY; KIDNEY TUMOR; METABOLISM; MORTALITY; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR RECURRENCE;

ANAPLASIA; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FRAMESHIFT MUTATION; GENETIC ASSOCIATION STUDIES; GENOMIC INSTABILITY; HUMANS; INFANT; KIDNEY; KIDNEY NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53; WILMS TUMOR;

EID: 84907963100     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109924     Document Type: Article

References (47)

1. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, et al. (1998) Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 16: 3744-3751.
2. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, et al. (2001) Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol 19: 3719-3724.
3. Breslow NE, Ou SS, Beckwith JB, Haase GM, Kalapurakal JA, et al. (2004) Doxorubicin for favorable histology, Stage II-III Wilms tumor: results from the National Wilms Tumor Studies. Cancer 101: 1072-1080.
4. de Kraker J, Graf N, van Tinteren H, Pein F, Sandstedt B, et al. (2004) Reduction of postoperative chemotherapy in children with stage I intermediate-risk and anaplastic Wilms' tumour (SIOP 93-01 trial): a randomised controlled trial. Lancet 364: 1229-1235.
5. Pritchard-Jones K, Kelsey A, Vujanic G, Imeson J, Hutton C, et al. (2003) Older age is an adverse prognostic factor in stage I, favorable histology Wilms' tumor treated with vincristine monochemotherapy: a study by the United Kingdom Children's Cancer Study Group, Wilm's Tumor Working Group. J Clin Oncol 21: 3269-3275.
6. Green DM (2004) The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 22: 1366-1372.
7. Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L, Downie P, et al. (2013) Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol 14: e95-e103.
8. Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, et al. (2006) Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 42: 2554-2562.
9. Dome JS, Liu T, Krasin M, Lott L, Shearer P, et al. (2002) Improved survival for patients with recurrent Wilms tumor: the experience at St. Jude Children's Research Hospital. J Pediatr Hematol Oncol 24: 192-198.
10. Malogolowkin M, Cotton CA, Green DM, Breslow NE, Perlman E, et al. (2008) Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 50: 236-241.
11. Beckwith JB, Palmer NF (1978) Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer 41: 1937-1948.
12. Faria P, Beckwith JB, Mishra K, Zuppan C, Weeks DA, et al. (1996) Focal versus diffuse anaplasia in Wilms tumor-new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol 20: 909-920.
13. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, et al. (2006) Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol 24: 2352-2358.
14. Reinhard H, Schmidt A, Furtwangler R, Leuschner I, Rube C, et al. (2008) Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol Rep 20: 463-467.
15. Bardeesy N, Beckwith JB, Pelletier J (1995) Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 55: 215-219.
16. Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, et al. (1994) Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet 7: 91-97.
17. el Bahtimi R, Hazen-Martin DJ, Re GG, Willingham MC, Garvin AJ (1996) Immunophenotype, mRNA expression, and gene structure of p53 in Wilms' tumors. Mod Pathol 9: 238-244.
18. Malkin D, Sexsmith E, Yeger H, Williams BR, Coppes MJ (1994) Mutations of the p53 tumor suppressor gene occur infrequently in Wilms' tumor. Cancer Res 54: 2077-2079.
19. Takeuchi S, Bartram CR, Ludwig R, Royer-Pokora B, Schneider S, et al. (1995) Mutations of p53 in Wilms' tumors. Mod Pathol 8: 483-487.
20. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629.
21. Hill DA, Shear TD, Liu T, Billups CA, Singh PK, et al. (2003) Clinical and biologic significance of nuclear unrest in Wilms tumor. Cancer 97: 2318-2326.
22. Jadali F, Sayadpour D, Rakhshan M, Karimi A, Rouzrokh M, et al. (2011) Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor. Iran J Kidney Dis 5: 149-153.
23. Franken J, Lerut E, Van Poppel H, Bogaert G (2013) p53 Immunohistochemistry Expression in Wilms Tumor: A Prognostic Tool in the Detection of Tumor Aggressiveness. J Urol 189: 664-670.
24. Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, et al. (2011) Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor. Genes Chromosomes Cancer 50: 982-995.
25. Thorvaldsdottir H, Robinson JT, Mesirov JP (2013) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 14: 178-192.
26. Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38: e164.
27. Olshen AB, Venkatraman ES, Lucito R, Wigler M (2004) Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5: 557-572.
28. Venkatraman ES, Olshen AB (2007) A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23: 657-663.
29. Willenbrock H, Fridlyand J (2005) A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics 21: 4084-4091.
30. Rausch T, Jones DT, Zapatka M, Stutz AM, Zichner T, et al. (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 148: 59-71.
31. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, et al. (2009) Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41: 465-472.
32. Pritchard-Jones K, Moroz V, Vujanic G, Powis M, Walker J, et al. (2012) Treatment and outcome of Wilms' tumour patients: an analysis of all cases registered in the UKW3 trial. Ann Oncol 23: 2457-2463.
33. Dome JS, Fernandez CV, Mullen EA, Kalapurakal JA, Geller JI, et al. (2013) Children's Oncology Group's 2013 blueprint for research: renal tumors. Pediatr Blood Cancer 60: 994-1000.
34. Smets AM, van Tinteren H, Bergeron C, De Camargo B, Graf N, et al. (2012) The contribution of chest CT-scan at diagnosis in children with unilateral Wilms' tumour. Results of the SIOP 2001 study. Eur J Cancer 48: 1060-1065.
35. Breslow NE, Lange JM, Friedman DL, Green DM, Hawkins MM, et al. (2010) Secondary malignant neoplasms after Wilms tumor: an international collaborative study. Int J Cancer 127: 657-666.
36. Termuhlen AM, Tersak JM, Liu Q, Yasui Y, Stovall M, et al. (2011) Twenty-five year follow-up of childhood Wilms tumor: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 57: 1210-1216.
37. Scott RH, Stiller CA, Walker L, Rahman N (2006) Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 43: 705-715.
38. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19: 607-614.
39. Hanel W, Moll UM (2012) Links between mutant p53 and genomic instability. J Cell Biochem 113: 433-439.
40. Zenz T, Krober A, Scherer K, Habe S, Buhler A, et al. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112: 3322-3329.
41. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, et al. (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A 100: 11547-11552.
42. Riley T, Sontag E, Chen P, Levine A (2008) Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402-412.
43. Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, et al. (2013) Effects of TP53 Mutational Status on Gene Expression Patterns Across Ten Human Cancer Types. J Pathol.
44. Pfeifer GP, Hainaut P (2011) Next-generation sequencing: emerging lessons on the origins of human cancer. Curr Opin Oncol 23: 62-68.
45. Miller MA, Karacay B, Breslow NE, Li S, O'Dorisio MS, et al. (2005) Prognostic value of quantifying apoptosis factor expression in favorable histology wilms tumors. J Pediatr Hematol Oncol 27: 11-14.
46. Segers H, van den Heuvel-Eibrink MM, de Krijger RR, Pieters R, Wagner A, et al. (2012) Defects in the DNA mismatch repair system do not contribute to the development of childhood Wilms tumors. Pediatr Dev Pathol.
47. Diniz G, Aktas S, Cubuk C, Ortac R, Vergin C, et al. (2013) Tissue expression of MLH1, PMS2, MSH2, and MSH6 proteins and prognostic value of microsatellite instability in Wilms tumor: experience of 45 cases. Pediatr Hematol Oncol 30: 273-284.